Foghorn Therapeutics Announces Closing of $50 Million Registered Direct Financing at a 30% Premium
Foghorn Therapeutics Highlights January Equity Financing, Program Progress and Strategic Objectives for 2026
Foghorn Therapeutics (NASDAQ:FHTX) was upgraded by analysts at
Wall Stre
Foghorn Therapeutics (NASDAQ:FHTX) was upgraded by analysts at BTIG Research to a "strong-buy" rating.
Foghorn Therapeutics (NASDAQ:FHTX) is now covered by analysts at BTIG Research. They set a "buy" rating on the stock.